Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.4% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health (HIMS) has recently broadened its telehealth services beyond diagnostics, hormone health, and weight-loss support. The company's goal is to enhance its range of services and extend its global reach through the acquisition of Zava.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 5.4% on Jan 21, 2026 16:15

• The decline in HIMS stock today might be linked to investors taking profits following a period of growth, resulting in a temporary drop in the stock price.
• Despite the company's ambitious expansion strategies and revenue forecasts, investor apprehension about potential regulatory scrutiny and competition in the GLP-1 weight-loss sector may have adversely affected the stock price.
• The uncertainties surrounding HIMS' ability to effectively address these challenges and meet its revenue and earnings targets by 2028 could have contributed to investors' pessimistic outlook, causing a decrease in the stock price.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Is Hims & Hers (HIMS) Using Zava to Balance GLP-1 Uncertainty with Broader Platform Ambitions?

Hims & Hers Health has expanded its telehealth platform beyond its original focus, entering diagnostics, hormone health, and weight-loss support, and extending its reach into Europe through the Zava acquisition. This expansion aims to diversify its offerings and international growth, potentially offsetting risks associated with regulatory scrutiny and competition in its GLP-1 weight-loss sector. The company projects significant revenue and earnings growth by 2028, with its fair value estimated at $44.36, presenting a 42% upside from its current price.

https://www.sahmcapital.com/news/content/is-hims-hers-hims-using-zava-to-balance-glp-1-uncertainty-with-broader-platform-ambitions-2026-01-15

Trending Today

Bittensor ($TAO) Crypto Forecast: Up 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 16.9% Today

Halliburton Company ($HAL) Stock Forecast: Up 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 6.8% Today

Citizens Financial Group Inc. ($CFG) Stock Forecast: Up 6.8% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 18.5% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 20.0% Today

Power Integrations Inc. ($POWI) Stock Forecast: Up 5.9% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 5.7% Today

Hims & Hers Health Inc. Price History

17.10.2025 - HIMS Stock was down 5.4%

• The rollout of Labs accompanied by yearly plans for comprehensive testing from Hims & Hers Health (NYSE: HIMS) potentially generated optimistic investor attention and sentiment.
• However, the decline in stock price could be linked to competitive activities overshadowing the company's positive disclosures, raising potential investor apprehensions.
• Despite Hims & Hers expanding its technology-driven healthcare model with new services, selling pressure and market dynamics may have contributed to the stock's downward trajectory.
• Investor sentiment towards HIMS appears to be influenced by both company-specific updates and broader market conditions, leading to the observed bearish movement today.

21.00.2026 - HIMS Stock was down 5.4%

• The decline in HIMS stock today might be linked to investors taking profits following a period of growth, resulting in a temporary drop in the stock price.
• Despite the company's ambitious expansion strategies and revenue forecasts, investor apprehension about potential regulatory scrutiny and competition in the GLP-1 weight-loss sector may have adversely affected the stock price.
• The uncertainties surrounding HIMS' ability to effectively address these challenges and meet its revenue and earnings targets by 2028 could have contributed to investors' pessimistic outlook, causing a decrease in the stock price.

12.00.2026 - HIMS Stock was up 6.5%

• The bullish movement in HIMS stock today could be attributed to:
• Positive long-term outlook despite weak nearand mid-term sentiment.
• Trading systems reacting to the stock's volatility, potentially driving increased buying interest.
• The AI models generating multiple trading strategies to manage the current breakdown and downside risk.
• Investors might be optimistic about the company's future growth prospects and the potential of its telehealth and wellness products, leading to increased buying pressure and driving the stock price higher.

05.10.2025 - HIMS Stock was up 5.2%

• Q3 earnings were in line with estimates and revealed a revenue surprise of +2.62%.
• HIMS stock experienced a significant surge post-earnings, potentially influenced by discussions regarding new product offerings on its platform.
• The company's emphasis on expanding AI-driven personalized health and wellness services, coupled with a substantial funding increase, likely influenced the favorable market sentiment.
• Market observations suggest that investors perceive HIMS as a valuable investment compared to other companies in the same sector.

13.10.2025 - HIMS Stock was down 5.5%

• HIMS' ongoing global expansion of AI-driven personalized and subscription-based care, supported by recent funding, indicates a promising growth trajectory.
• Despite these positive developments, market sentiment turned bearish, possibly reflecting concerns regarding the scalability and profitability of new offerings in GLP-1 weight loss, hormone health, and custom treatments.
• Investor caution might stem from doubts about the company's ability to effectively monetize its technology-driven care model in the competitive healthcare sector, contributing to today's bearish stock movement.

11.10.2025 - HIMS Stock was down 5.7%

• HIMS stock took a hit today despite expanding its AI-driven personalized and subscription-based care globally, indicating a disconnect between company growth and market sentiment.
• The decline in third-quarter earnings and contracting margins likely contributed to the bearish movement, overshadowing the positive revenue and subscriber growth.
• The comparison with Omnicell in terms of value may have also influenced investor perception, potentially leading to profit-taking and selling pressure on HIMS stock.
• Overall, the combination of earnings disappointment, margin concerns, and valuation comparisons could have fueled the bearish sentiment surrounding HIMS stock today.

04.10.2025 - HIMS Stock was up 5.2%

• HIMS met Q3 earnings expectations and surpassed revenue forecasts, suggesting a robust financial performance.
• Talks about potentially offering Novo Nordisk's products on its platform were well-received by investors, contributing to an optimistic market response and driving up the stock price.
• Positive investor sentiment was fueled by the company's expansion strategies, introduction of new products, and a significant increase in funding.
• The expectation of sustained product demand and heightened platform engagement prior to the earnings release also played a part in the stock's upward movement.

23.11.2025 - HIMS Stock was down 5.0%

• The stock analysis for HIMS suggests weak near and mid-term sentiment despite a positive long-term outlook.
• AI-generated trading strategies indicate elevated downside risk, particularly due to a lack of additional long-term support signals.
• The market movement could be attributed to investors reacting to the increased risk levels and lack of near-term positive catalysts for the company.
• Overall, the bearish movement in HIMS today may be a result of the cautious sentiment surrounding the stock's short to mid-term prospects, as highlighted in the analysis.

20.10.2025 - HIMS Stock was down 5.7%

• The stock faced selling pressure, resulting in a decrease in value.
• Despite launching new services such as Labs for comprehensive testing, external factors may have overshadowed positive developments.
• Investor comparisons with other stocks like OMCL could have contributed to the bearish trend.
• Market dynamics and general investor sentiment towards telehealth and wellness firms likely influenced today's decline in the stock price.

21.10.2025 - HIMS Stock was down 6.9%

• The optimism from significant investors towards Hims & Hers Health did not result in a rise in the stock's value, with noticeable selling pressure impacting its performance.
• Despite launching new health testing services through Labs with annual plans, HIMS shares declined, potentially due to external competitive factors influencing investor confidence.
• The market shift may be linked to increased selling activity, signaling a change in market dynamics despite favorable company updates.
• A comparison with another company's stock (OMCL vs. HIMS) implies that investors could be reconsidering their positions in HIMS, contributing to the bearish trend witnessed today.

06.10.2025 - HIMS Stock was down 8.9%

• Third-quarter earnings for HIMS were down compared to the previous year, despite notable growth in revenue and subscribers.
• Investors are currently comparing HIMS to similar companies like Omnicell in the medical information systems sector to evaluate the more attractive investment.
• HIMS met earnings predictions for the third quarter, outperforming revenue expectations. This resulted in a brief stock increase following the earnings disclosure.
• The market reacted negatively to talks about potential associations with Novo Nordisk to provide specific medications through their platform, potentially contributing to the downward trend in the stock.

10.11.2025 - HIMS Stock was down 5.4%

• The bearish movement in HIMS stock today could be attributed to the securities fraud class action lawsuit filed against the company. The allegations of deceptive promotion of illegitimate versions of Wegovy, jeopardizing its collaboration with Novo Nordisk, have raised concerns among investors.
• The negative news about the lawsuit may have led to a loss of investor confidence in Hims & Hers Health Inc., resulting in a significant downward pressure on the stock price.
• Investors are likely reacting to the potential risks associated with the allegations, causing a sell-off of HIMS shares as they reassess the company's credibility and future prospects in the telehealth industry.